text_1: Roche's schizophrenia drug misses goal in two late-stage trials.
text_2: An experimental Roche drug designed to treat the “negative symptoms” of schizophrenia failed to meet its main goal in two late-stage studies, dealing a blow to the Swiss drugmaker’s research hopes in the risky area of brain science.